检索结果-南通市图书馆

hepatocellular carcinoma recurrence after liver transplant:An Australian single-centre study

World Journal of Transplantation 2025年第1期15卷 105-114页

作者： Matthew G Garas Luis Calzadilla-Bertot Briohny W Smith Luc Delriviere Byron Jaques Lingjun Mou Leon A Adams Gerry C MacQuillan George Garas Gary P Jeffrey Michael C Wallace Medical School University of Western AustraliaNedlands 6009Western AustraliaAustralia Department of Hepatology Sir Charles Gairdner HospitalNedlands 6009Western AustraliaAustralia Department of Surgery Sir Charles Gairdner HospitalNedlands 6009Western AustraliaAustralia

BACKGROUND hepatocellular carcinoma(HCC)is a leading cause of cancer-related deaths *** transplantation(LT)offers the most effective *** recurrence is the strongest risk factor that decreases post-LT survival in patients transplanted for *** rate of HCC recurrence is generally reported as 8%-20%in the *** predictors of HCC have already been researched,however,to our knowledge there are no published studies on this topic using Australian *** To determine the rate and identify predictors of HCC recurrence in a contemporary Western Australian LT *** We performed a retrospective cohort study of all liver transplants in patients with HCC at Sir Charles Gairdner Hospital between 2006 and *** was collected from various health record databases and included recipient demographics,serum biochemistry,radiology,operation notes,explant histopathology and details of *** survival of HCC patients post-LT,stratified for recurrence,was calculated by Kaplan Meier *** and multivariate Cox regression was used to determine predictors of HCC recurrence *** Between 1/1/2006 and 12/31/2021,119 patients were transplanted with HCC.8.4%of subjects developed recurrent HCC after LT with median follow-up time of 5.4 *** median time to recurrence was 2.9 years±0.75 *** comparing baseline characteristics,a greater proportion of subjects with recurrence had common characteristics on explant histopathology,including>3 viable nodules(P=0.001),vascular invasion(P=0.003)and poorly differentiated HCC(P=0.03).Unadjusted survival curves showed lower 1-year,3-year,5-year and 10-year survival rates in subjects with HCC recurrence compared to those without HCC recurrence(90%vs 92%,70%vs 88%,42%vs 80%,14%vs 76%,respectively;log rank P<0.001).CONCLUSION HCC recurrence was low at 8.4%in this contemporary Australian cohort,however it significantly impacted post-LT *** studies are requir

关键词： Liver cancer Recurrence Liver transplantation hepatocellular carcinoma Predictors Post-transplant survival Australian data

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Predictive value of a constructed artificial neural network model for microvascular invasion in hepatocellular carcinoma:A retrospective study

引用

World Journal of Gastrointestinal Oncology 2025年第1期17卷 88-100页

作者： Hai-Yang Nong Yong-Yi Cen Shan-Jin Lu Rui-Sui Huang Qiong Chen Li-Feng Huang Jian-Ning Huang Xue Wei Man-Rong Liu Lin Li Ke Ding Department of Radiology The Third Affiliated Hospital of Guangxi Medical UniversityNanning 530031Guangxi Zhuang Autonomous RegionChina Department of Radiology Affiliated Hospital of Youjiang Medical University for NationalitiesBaise 533000Guangxi Zhuang Autonomous RegionChina Guangxi Clinical Medical Research Center for Hepatobiliary Diseases Affiliated Hospital of Youiiang Medical University for NationalitiesBaise 533000Guangxi Zhuang Autonomous RegionChina Department of Ultrasound The Third Affiliated Hospital of Guangxi Medical UniversityNanning 530031Guangxi Zhuang Autonomous RegionChina Department of Hepatobiliary Surgery The Third Affiliated Hospital of Guangxi Medical UniversityNanning 530031Guangxi Zhuang Autonomous RegionChina

BACKGROUND Microvascular invasion(MVI)is a significant risk factor for recurrence and metastasis following hepatocellular carcinoma(HCC)***,there is a paucity of preoperative evaluation approaches for *** To investigate the predictive value of texture features and radiological signs based on multiparametric magnetic resonance imaging in the non-invasive preoperative prediction of MVI in *** Clinical data from 97 HCC patients were retrospectively collected from January 2019 to July 2022 at our *** were classified into two groups:MVI-positive(n=57)and MVI-negative(n=40),based on postoperative pathological *** correlation between relevant radiological signs and MVI status was ***4.6 software and the mutual information method were employed to identify the top 10 dominant texture features,which were combined with radiological signs to construct artificial neural network(ANN)models for MVI *** predictive performance of the ANN models was evaluated using area under the curve,sensitivity,and *** models with relatively high predictive performance were screened using the DeLong test,and the regression model of multilayer feedforward ANN with backpropagation and error backpropagation learning method was used to evaluate the models’*** The absence of a pseudocapsule,an incomplete pseudocapsule,and the presence of tumor blood vessels were identified as independent predictors of HCC *** ANN model constructed using the dominant features of the combined group(pseudocapsule status+tumor blood vessels+arterial phase+venous phase)demonstrated the best predictive performance for MVI status and was found to be automated,highly operable,and very *** The ANN model constructed using the dominant features of the combined group can be recommended as a noninvasive method for preoperative prediction of HCC MVI status.

关键词： hepatocellular carcinoma Texture analysis Magnetic resonance imaging Microvascular invasion Pseudocapsule Tumor blood vessels

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Loss-of-function mutations of microRNA-142-3p promote ASH1L expression to induce immune evasion and hepatocellular carcinoma progression

引用

World Journal of Gastroenterology 2025年第1期31卷 126-145页

作者： Xing-Hui Yu Yan Xie Jian Yu Kun-Ning Zhang Zhou-Bo Guo Di Wang Zhao-Xian Li Wei-Qi Zhang Yu-Ying Tan Li Zhang Wen-Tao Jiang School of Medicine Nankai UniversityTianjin 300192China Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer Tianjin First Center HospitalTianjin 300192China Department of Liver Transplantation Tianjin First Center HospitalTianjin 300192China First Central Clinical School Tianjin Medical UniversityTianjin 300192China

BACKGROUND hepatocellular carcinoma(HCC)has been a pervasive malignancy throughout the world with elevated *** therapeutic targets are beneficial to treat and predict the ***,the exact molecular mechanisms leading to the progression of HCC are still *** has shown that the microRNA-142-3p level decreases in HCC,whereas bioinformatics analysis of the cancer genome atlas database shows the ASH1L expression increased among liver tumor *** this paper,we will explore the effects and mechanisms of microRNA-142-3p and ASH1L affect the prognosis of HCC patients and HCC cell bioactivity,and the association between *** To investigate the effects and mechanisms of microRNA-142-3p and ASH1L on the HCC cell bioactivity and prognosis of HCC *** In this study,we grouped HCC patients according to their immunohistochemistry results of ASH1L with pathological tissues,and retrospectively analyzed the prognosis of HCC ***,explored the roles and mechanisms of microRNA-142-3p and ASH1L by cellular and animal experiments,which involved the following experimental methods:Immunohistochemical staining,western blot,quantitative real-time-polymerase chain reaction,flow cytometric analysis,tumor xenografts in nude mice,*** statistical methods involved in this study contained t-test,one-way analysis of variance,theχ^(2)test,the Kaplan-Meier approach and the log-rank *** In this study,we found that HCC patients with high expression of ASH1L possess a more recurrence rate as well as a decreased overall survival ***1L promotes the tumorigenicity of HCC and microRNA-142-3p exhibits reduced expression in HCC tissues and interacts with ASH1L through targeting the ASH1L 3′untranslated ***,microRNA-142-3p promotes apoptosis and inhibits proliferation,invasion,and migration of HCC cell lines in vitro via *** the exploration mechanism,we found ASH1L may promote an immunosuppressive mi

关键词： hepatocellular carcinoma MicroRNA-142-3p ASH1L Immune evasion Tumor immune microenvironment Apoptosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Interleukin-17A facilitates tumor progression via upregulating programmed death ligand-1 expression in hepatocellular carcinoma

引用

World Journal of Gastrointestinal Oncology 2025年第1期17卷 176-198页

作者： Zhong-Xia Yang Li-Ting Zhang Xiao-Jun Liu Xue-Bin Peng Xiao-Rong Mao The First School of Clinical Medicine Lanzhou UniversityLanzhou 730000Gansu ProvinceChina Department of Infectious Diseases The First Hospital of Lanzhou UniversityLanzhou 730000Gansu ProvinceChina Department of Radiotherapy Gansu Provincial HospitalLanzhou 730000Gansu ProvinceChina

BACKGROUND hepatocellular carcinoma(HCC)is an inflammation-associated tumor with a dismal *** has become an important treatment strategy for HCC,as immunity is closely related to inflammation in the tumor *** regulates the expression of programmed death ligand-1(PD-L1)in the immunosuppressive tumor microenvironment and affects im-munotherapy ***-17A(IL-17A)is involved in the remodeling of the tumor microenvironment and plays a protumor or antitumor role in different *** hypothesized that IL-17A participates in tumor progression by affe-cting the level of immune checkpoint molecules in *** upregulation of PD-L1 expression in HCC cells by IL-17A was assessed by reverse transcription PCR,western blotting,and flow *** studies were conducted with gene knockout models and pathway *** function of IL-17A in immune evasion was explored through coculture of T cells and HCC *** effects of IL-17A on the malignant biological behaviors of HCC cells were evaluated in vitro,and the antitumor effects of an IL-17A inhibitor and its synergistic effects with a PD-L1 inhibitor were studied in *** IL-17A upregulated PD-L1 expression in HCC cells in a dose-dependent manner,whereas IL-17A receptor knockout or treatment with a small mothers against decapentaplegic 2 inhibitor diminished the PD-L1 expression induced by ***-17A enhanced the survival of HCC cells in the coculture ***-17A increased the viability,G2/M ratio,and migration of HCC cells and decreased the apoptotic *** D1,VEGF,MMP9,and Bcl-1 expression increased after IL-17A treatment,whereas BAX expression *** combination of IL-17A and PD-L1 inhibitors showed synergistic antitumor efficacy and increased cluster of differentiation 8+T lymphocyte infiltration in an HCC mouse *** IL-17A upregulates PD-L1 expression via the IL-17A receptor/phosphorylation-small mothers against

关键词： Interleukin-17A Programmed death ligand-1 Interleukin-17A receptor Small mothers against decapentaplegic 2 hepatocellular carcinoma Immunotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Antiviral therapy for hepatitis B virus infection is beneficial for the prognosis hepatocellular carcinoma

引用

World Journal of Gastrointestinal Oncology 2025年第1期17卷 1-9页

作者： Hui Wan Yu-Xin Zhang Guan-Yue Shan Jun-Ya Cheng Duan-Rui Qiao Yi-Ying Liu Wen-Na Shi Hai-Jun Li Institute of Translational Medicine The First Hospital of Jilin UniversityChangchun 130061Jilin ProvinceChina Department of Bioengineering Pharmacy School of Jilin UniversityChangchun 130061Jilin ProvinceChina Institute of Liver Diseases Institute of Translational MedicineThe First Hospital of Jilin UniversityChangchun 130061Jilin ProvinceChina

In this editorial,we comment on the article by Mu et al,published in the recent issue of the World Journal of Gastrointestinal *** pay special attention to the immune tolerance mechanism caused by hepatitis B virus(HBV)infection,the pathogenesis of hepatocellular carcinoma(HCC),and the role of antiviral therapy in treating HCC related to HBV *** infection leads to systemic innate immune tolerance by directly inhibiting pattern recognition receptor recognition and antiviral signaling pathways,as well as by inhibiting the immune functions of macrophages,natural killer cells and dendritic *** addition,HBV leads to an immunosuppressive cascade by expressing inhibitory molecules to induce exhaustion of HBV-specific cluster of differentiation 8+T cells,ultimately leading to long-term viral *** loss of immune cell function caused by HBV infection ultimately leads to ***-term antiviral therapy can improve the prognosis of patients with HCC and prevent tumor recurrence and metastasis.

关键词： Hepatitis B virus hepatocellular carcinoma Hepatitis B virus-DNA Immune tolerance Antiviral therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Advanced hepatocellular carcinoma treatment strategies:Are transarterial approaches leading the way?

引用

World Journal of Gastrointestinal Oncology 2025年第1期17卷 22-27页

作者： Stefan Patauner Giovanni Scotton Francesca Notte Antonio Frena Department of General and Pediatric Surgery Bolzano Central Hospital-SABESBolzano 39100Trentino-Alto AdigeItaly

hepatocellular carcinoma(HCC)is a leading cause of cancer-related mortality worldwide,with advanced stages posing significant treatment ***-though hepatic arterial infusion chemotherapy(HAIC)has emerged as a promising modality for treating advanced HCC,particularly in Asian clinical practice,its adoption in Western medicine remains limited due to a lack of large-scale randomized controlled *** editorial reviews and comments on the meta-analysis conducted by Zhou et al,which evaluates the efficacy and safety of HAIC and its combination strategies for advanced *** authors performed a comprehensive meta-analysis of various clinical trials and cohort studies comparing HAIC and its combinations to other first-line treatments,such as sorafenib and transarterial chemoembolization(TACE).In this work,HAIC showed significantly better results regarding overall survival and progression-free survival compared to sorafenib or TACE alone and their *** in combination with lenvatinib,ablation,programmed cell death 1 inhibitors,and radiotherapy further enhanced patient outcomes,indicating a synergistic *** editorial focuses on the critical role of multimodal treatment strategies in managing advanced *** advocates for a paradigm shift towards integrated treatment approaches to enhance survival rates and improve the quality of life in patients with advanced HCC.

关键词： hepatocellular carcinoma Hepatic arterial infusion chemotherapy Transarterial chemoembolization Sorafenib Combined therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma

引用

World Journal of Gastrointestinal Oncology 2025年第1期17卷 52-61页

作者： Fei-Da Wu Hai-Feng Zhou Wei Yang Di Zhu Bi-Fei Wu Hai-Bin Shi Sheng Liu Wei-Zhong Zhou Department of Interventional Radiology The First Affiliated Hospital of Nanjing Medical UniversityNanjing 210029Jiangsu ProvinceChina

BACKGROUND hepatocellular carcinoma(HCC)is the most common form of liver cancer that has limited treatment options and a poor *** chemoembolization(TACE)is the first-line treatment for intermediate-stage HCC but can induce tumour hypoxia,thereby promoting *** studies suggested that combining TACE with anti-angiogenic therapies and immunotherapy might im-prove ***,a tyrosine kinase inhibitor,has demonstrated superior outcomes compared to sorafenib,while immune checkpoint inhibitors such as sintilimab show potential when combined with ***,the efficacy and safety of TACE combined with lenvatinib and sintilimab(TACE+SL)compared to TACE with lenvatinib alone(TACE+L)in patients with intermediate-ad-vanced HCC has not yet been *** To evaluate the efficacy and safety of TACE+SL therapy in comparison to TACE+L therapy in patients with intermediate-advanced *** A retrospective analysis was performed on patients with intermediate-advanced HCC who received TACE plus lenvatinib with or without sintilimab between September 2019 and September *** characteristics were compared,and propensity score matching was *** survival(OS),progression-free survival(PFS),and objective response rate(ORR)were evaluated between the two groups,and adverse events were *** The study included 57 patients,with 30 in the TACE+SL group and 27 in the TACE+L *** TACE+SL group demonstrated significantly improved median PFS and OS compared to the TACE+L group(PFS:14.1 months vs 9.6 months,P=0.016;OS:22.4 months vs 14.1 months,P=0.039),along with a higher ORR(70.0%vs 55.6%).After propensity score matching,30 patients were included,with the TACE+SL group again showing longer median PFS and a trend toward improved OS(PFS:14.6 months vs 9.2 months,P=0.012;OS:23.9 months vs 16.3 months,P=0.063),and a higher ORR(73.3%vs 53.3%).No severe adverse events were *** TACE+SL demonstrat

关键词： hepatocellular carcinoma Transarterial chemoembolization Sintilimab Lenvatinib Immunotherapy Programmed cell death 1 Prognosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Trends of alkaline phosphatase to prealbumin ratio in patients with hepatitis B linked to hepatocellular carcinoma development

引用

World Journal of Gastroenterology 2025年第2期31卷 42-51页

作者： Wen-Chong Zhen Jing Sun Xue-Ting Bai Qian Zhang Zi-Han Li Yi-Xin Zhang Rong-Xuan Xu Wei Wu Zhi-Han Yao Chun-Wen Pu Xiao-Feng Li School of Public Health Dalian Medical UniversityDalian 116044Liaoning ProvinceChina Graduate School Dalian Medical UniversityDalian 116044Liaoning ProvinceChina Dalian Public Health Clinical Center Dalian Municipal Research Institute for Public HealthDalian 116001Liaoning ProvinceChina Department of Epidemiology and Health Statistics Dalian Medical UniversityDalian 116044Liaoning ProvinceChina

BACKGROUND Chronic hepatitis B often progresses silently toward hepatocellular carcinoma(HCC),a leading cause of mortality *** detection of HCC is crucial,yet *** To investigate the role of dynamic changes in alkaline phosphatase to prealbumin ratio(APR)in hepatitis B progression to *** Data from 4843 patients with hepatitis B(January 2015 to January 2024)were *** incidence rates in males and females were compared using the log-rank *** were evaluated using Kaplan–Meier *** Linear Mixed-Effects Model was applied to track the fluctuation of APR levels over ***,Joint Modeling of Longitudinal and Survival data was employed to investigate the temporal relationship between APR and HCC *** The incidence of HCC was higher in *** ensure the model’s normality assumption,this study applied a logarithmic transformation to APR,yielding *** levels were higher in females(t=5.26,P<0.01).A 1-unit increase in ratio correlated with a 2.005-fold higher risk of HCC in males(95%CI:1.653-2.431)and a 2.273-fold higher risk in females(95%CI:1.620-3.190).CONCLUSION Males are more prone to HCC,while females have higher APR *** no baseline APR link,rising APR indicates a higher HCC risk.

关键词： Alkaline phosphatase to prealbumin ratio Chronic hepatitis B patients hepatocellular carcinoma Retrospective cohort study Linear Mixed-Effect Mode Joint Modelling of Longitudinal and Survival data

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

WNT/β-catenin-M2 macrophage interplay as a target for therapy against hepatocellular carcinoma:Role of Calculus bovis

引用

World Journal of Gastroenterology 2025年第3期31卷 130-133页

作者： Tryfonas Mpektsis Anastasios Manolakis Andreas Kapsoritakis Department of Gastroenterology University Hospital of LarisaLarisa 41100Greece

Liver cancer,and in particular hepatocellular carcinoma(HCC)is a disease of rising prevalence and *** date,definitive treatment options include either surgical excision or ablation of the affected *** increasing research on several pathways that could be involved in the progression of HCC,new elements within these pathways emerge as potential targets for novel *** WNT/β-catenin pathway favors the presence of M2 tumor-associated macrophages which in turn promote tumor growth and *** inhibition of this pathway is considered a good candidate for such targeted therapeutic ***,as Huang et al show in their recently published article,Calculus bovis which is used in traditional Chinese medicine can exert an inhibitory effect on theβ-catenin pathway and become a potential candidate for targeted pharmacotherapy against liver cancer.

关键词： hepatocellular carcinoma Calculus bovis WNT/β-catenin pathway Tumorassociated macrophages

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

TRIPLET combined with microwave ablation:A novel treatment for advanced hepatocellular carcinoma

引用

World Journal of Gastrointestinal Oncology 2025年第1期17卷 10-12页

作者： Fei-Yu Zhao Guo-Wei Si Nian-Song Qian Department of Thoracic Oncology Respiratory and Critical Care MedicineThe Eighth Medical Center of People’s Liberation Army General HospitalBeijing 100853China Department of Gastroenterology Fourth Medical CentreGeneral Hospital of the People's Liberation ArmyBeijing 100142China Senior Department of Thoracic Oncology Respiratory and Critical Care MedicineThe Eighth Medical Center of People’s Liberation Army General HospitalBeijing 100091China

This editorial comments on a study by Zuo et *** focus is on the efficacy of he-patic arterial infusion chemotherapy combined with camrelizumab and apatinib(the TRIPLET regimen),alongside microwave ablation therapy,in treating advanced hepatocellular carcinoma(HCC).The potential application of this combination therapy for patients with advanced HCC is evaluated.

关键词： Microwave ablation Hepatic arterial infusion chemotherapy Apatinib Camrelizumab hepatocellular carcinoma

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：